Nomlabofusp - Larimar Therapeutics
Alternative Names: CTI 1601; Tat-frataxin; TAT-FXNLatest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Indiana University; Wake Forest University School of Medicine
- Developer Larimar Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Frataxin protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Friedreich's ataxia
Most Recent Events
- 16 Dec 2024 Safety, efficacy and pharmacokinetics data from a phase II trial in Friedreich's ataxia released by Larimar Therapeutics
- 06 Dec 2024 Phase-I clinical trials in Friedreich's ataxia (In children, In adolescents) in USA (SC), , (NCT06681766),
- 08 Nov 2024 Larimar Therapeutics plans a phase I trial for Friedreich's ataxia (In children, In adolescents) in the US (SC) (NCT06681766)